VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
1.580
-0.120 (-7.06%)
Mar 31, 2025, 4:00 PM EDT - Market closed
VYNE Therapeutics Revenue
In the year 2024, VYNE Therapeutics had annual revenue of $501.00K with 18.16% growth. VYNE Therapeutics had revenue of $84.00K in the quarter ending December 31, 2024, with 10.53% growth.
Revenue (ttm)
$501.00K
Revenue Growth
+18.16%
P/S Ratio
144.52
Revenue / Employee
$38,538
Employees
13
Market Cap
23.43M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 501.00K | 77.00K | 18.16% |
Dec 31, 2023 | 424.00K | -53.00K | -11.11% |
Dec 31, 2022 | 477.00K | -454.00K | -48.76% |
Dec 31, 2021 | 931.00K | -20.06M | -95.57% |
Dec 31, 2020 | 20.99M | 20.55M | 4,638.83% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VYNE News
- 11 days ago - VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire
- 25 days ago - VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - VYNE Therapeutics to Participate in March Investor Conferences - GlobeNewsWire
- 5 weeks ago - VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - GlobeNewsWire
- 3 months ago - VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo - GlobeNewsWire
- 3 months ago - VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 7 months ago - VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 8 months ago - VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire